O- -L-TYROSINE

PreclinicalSmall molecule

UUniversity Hospital, Toulouse

O- -L-TYROSINE is one of 28 small molecule programs targeting Low Grade Glioma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Grade GliomaActive, not recruiting

Low Grade GliomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Low Grade Glioma

#DrugCompanyPhaseTrials

Tafinlar

Novartis

Approved

1 2

Mektovi

Pfizer

Approved

—3

Plaquenil

Alnylam Pharmaceuticals

Approved

—4

Rapamune

PPrism Pharmaceuticals

Approved

—5

Navelbine

PPierre Fabre Medicament

Approved

—6

Caprelsa

GGenzyme, a Sanofi Company

Approved

—7

Tasigna

AAzurity Pharmaceuticals

Koselugo

2 9

Oncovin

Eli Lilly

Phase 3

1 10

Paraplatin

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Low Grade Glioma1 trial

Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma

Completed·UUniversity Hospital, Toulouse·N/A·NCT02286531·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for O- -L-TYROSINE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — O- -L-TYROSINE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for O- -L-TYROSINE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Toulouse

O- -L-TYROSINE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Low Grade Glioma1 trial

References

Drug Info

Quick Facts

Related News